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Abstract 
Antibiotic laden bone cements are regularly employed to prevent infections after joint replacement 
surgeries. We have developed silica nanocarriers loaded with gentamicin as a drug delivery systems to 
be dispersed in Poly-methyl-methacrylate (PMMA) bone cement for controlling and extending the 
release of the antibiotic from bone cements, thus proving a prolonged antimicrobial activity,. Layer-
by-Layer self-assembly was used to deposit gentamicin between alginate layers and two different 
Poly-beta-amino esters on the silica nanoparticles.   
The release of gentamicin from PMMA bone cement containing silica nanocarriers continued for 
about 30 days compared to 6 days when the same amount of antibiotic was added as pure powder (as 
in commercial formulations); moreover the media containing the released antimicrobial drug was 
capable of preventing the growth of numerous bacteria species responsible for prosthetic joint 
infections (both catalogue strains and clinical isolates) for longer periods of time than  in case of 
commercial formulation; thus confirming the extended antimicrobial properties of the drug once 
released from the carrier. 
No detrimental effects toward human osteoblasts were also observed; moreover bone cement material 
characteristics such as curing time, water uptake and mechanical properties were unaffected when the 
silica nanocarriers were added. 
  
  
1 Introduction 
About 67 thousand and 80 thousand joint replacement surgeries were performed in England and 
Wales in 2017 1 for hip and knee respectively. These procedures are  carried out on a growing number 
of patients because of the success in improving life quality and because of the  aging population, 
along with obesity one of the risk factors leading to joint damage. Poly-methyl-methacrylate (PMMA) 
bone cement is commonly employed to fix arthroplasty devices to bones; the use of such material is 
due to the quick setting time and good mechanical properties of the PMMA bone cement 2 .  
Post operatory infections can occur after any surgery and they pose additional costs directly to 
healthcare providers by means of increased medicinal treatments and prolonged hospital stays. They 
are also a serious risk for the patients as such infections can have life threatening/changing impacts.  
Infections incidence of about 1-2 % was observed depending on the joint affected by the surgery 3 ,4 ; 
additionally, infections are more likely to develop after revision than after primary surgery 5 .  
Revision surgery cost in case of PJI (~21,000£) is almost twice the cost of the cost of the same 
procedure in non-infected cases (~11,000£) because operating times are longer, greater blood losses 
and higher rates of complications and extended hospitalisation (length of stay) 6 . The overall 
economic impact of PJI to American health care system had been estimated at $566 million in 2009 
only for the hospital direct costs (therefore neglecting all indirect costs i.e. lost productivity of patients 
and/or carer and other direct cost such as further GP visits and rehabilitation) with the forecast to 
reach $1.62 billion in 2020 7 . 
Antibiotics are commonly added to bone cements in order to prevent infections. Bone cement 
containing gentamicin or tobramycin 2- 4% w/w (Palacos R+G and Simplex with gentamicin) are 
commercially available and routinely employed in joint replacement surgeries. Antibiotic mixing 
results in not uniform distribution in the bone cement, leading to an uncontrolled release . Mainly, the 
antibiotic release occurs during the first few days (about a week) after implantation hence this 
approach does not protect against the infections that occur in the months after the surgery. 5  The 
general consensus is that early infections are caused by bacteria that enter the patient body through the 
surgical wound (exogenous) and immediately grow resulting in tissue damage; on the contrary late 
  
infections are assumed to be caused by bacteria that enter the organisms through other access points 
(haematogenous) i.e. any other minor wounds or orally, considerable time after the surgery and reach 
the joint replacement device through the blood stream 8 ,9 . The abiotic surface of the device 
constitutes a favourable environment to microorganism biofilm formation and growth. Therefore late 
infection are not caused by microorganisms penetrating the wound during or shortly after surgery and 
surviving the initial antimicrobial activity of the antibiotic bone cement but caused by bacteria that 
reach the joint replacement device at a later stage 10 . Hence, the ideal bone cement should provide 
antimicrobial activity for extended period of time in order to exhibit a prophylactic action against late 
infection offset; this could be achieved through the application of drug delivery systems 11 . For this 
purpose antibiotics delivery systems have been prepared through various techniques, for example 
tethering the drug to a surface 12 -14  or to a particle 15 -18 ; encapsulating the active molecule in 
nanoparticles 19  or liposomes 20  or depositing the drug  using Layer-by-Layer (LbL) assembly21 ,22 . 
Such multitude of approaches demonstrates the clear clinical need of an antimicrobial delivery system 
for bone cement; however it also reveals the still unsatisfactory performance of the available 
approaches. For example the entrapment of antibiotic in mesoporous silica coated with hydrolysable 
polymers suffers the trade-off between extended efficacy and immediate release; in order to extend 
the release, thicker coatings are required but this, in turn, prevents release in the first hours/days of 
contact with fluids 23 . Other approaches, like nano-tubes, hydroxyapatite nano-rods or liposomes, 
despite providing an improved release profile, had detrimental effects on bone cement mechanical 
properties seriously impinging on the practical application of such technologies 24 ,25 . Layer-by-Layer 
self-assembly is a coating technique employing oppositely charges polyelectrolyte adsorbed onto a 
charged surface alternatively 26 ,27 . It also widely used in medical devices as it is possible to embed 
drugs into LbL constructs replacing a polyelectrolyte with the chosen drug or conjugating the drug to 
one of the polyelectrolytes 28 ,29 . 
We hypothesised that silica nanoparticles containing antibiotics through LbL could extend antibiotic 
release when embedded in PMMA bone cement. In this work, Layer-by-Layer coatings have been 
prepared on silica nanoparticles using gentamicin and two different poly-beta-amino-esters (PBAEs). 
  
Silica nanoparticles are widely used as drug carriers because their blood compatibilitye30 -33  and we 
have shown that it is possible to achieve prolonged (few weeks) gentamicin release from silica 
nanoparticles coated with gentamicin using LbL while release is sustained for only a few days when 
conjugation is employed 34 . Gentamicin is aminoglycoside antibiotic with large-spectrum activity 35  
and despite rising resistance, it is still widely used in orthopaedic applications 36  and embedded into 
bone cement 37 .  
PBAE constitutes a class of positively charged and hydrolysable polyelectrolytes, have been shown to 
be better suited to prepare LbL constructs capable of sustained gentamicin release for prolonged 
periods of time compared to other polyelectrolytes such as chitosan 34 ,38 . 
The properties of the nanoparticles have been determined and the release profiles from PMMA bone 
cement was established. Furthermore, the antimicrobial activity of the released drug has been tested 
along with the material properties of the nanocomposite bone cement in order to ascertain that the 
addition of the silica nanocarriers to the PMMA bone cement did not compromise other functional 
properties of the orthopaedic material.   
2 Materials and Methods 
2.1 Chemicals 
Gentamicin sulphate, tetraethyl-orthosilicate (TEOS), 3-aminopropyltriethoxysilane (APTS), 1,4 
butanediol diacrylate, Piperazine, 4,4′-Trimethylenedipiperidine, ortho-phthaldialdehyde reagent 
solution (OPA) and sodium alginate (Mw 80.000-120.000 Da)were purchased from Sigma-Aldrich.  
Triton X-100, ammonium hydroxide (29.6 %), cyclohexane, n-hexanol, Dichloromethane (DCM), 
diethyl-ether, isopropyl alcohol and methanol were purchased from Fisher Scientific.  
All chemicals were used as-received. 
2.2 Synthesis silica nanoparticles 
Silica nanoparticles (SiO2) were prepared by hydrolysis of TEOS in reverse microemulsion and amino 
functionalised with APTS.38    
  
2.3 Polymer synthesis 
Piperazine or 4,4′-Trimethylenedipiperidine (Sigma, UK) were used as amine monomers. Amino 
terminated poly(-amino ester)s were synthesized by mixing 1,4 butanediol diacrylate and amine 
monomers in a 1:1.1 ratio in Dichloro-methane (DCM) at a concentration of 5ml of DCM per 3.7 
mmol of acrylate.38  
PBAEs prepared using piperazine and 4,4'-trimethylendipiperidine will be referred as POLY1 and 
POLY2 through the text, respectively (Figure 1a). 
 
 
Figure 1. (a) Reaction scheme and structure of POLY1 and POLY2. (b) PBAE hydrolysis in PBS for 
POLY1 () and POLY2 (). 
 
  
2.4 Gel permeation chromatography (GPC) 
The determination of the kinetics of hydrolysis of POLY1 and POLY2 was carried out through the 
reduction of molecular weight as determined by the FPLC (Fast Protein Liquid Chromatography) 
using Akta Design (Amersham pharmacia biotech-Sweden) supplied with Superdex 75 10/3000 GL 
column and acetate buffer pH 5 (1 ml/min) as mobile phase.38  
PBAEs solution (10 mg/ml) in PBS (pH 7.4) were prepared and incubated statically at 37°C; samples 
(0.5 ml) were collected and immediately analysed over 30 days. For each PBAE, two replicates were 
taken. A calibration curve was prepared using 7 standards with known molecular weights (purchased 
from Fluka Chemie AG and Polymer Laboratories Ltd) to correlate MW and retention volumes.38   
2.5 Layer-by-Layer deposition 
Gentamicin containing coatings were prepared on silica nanoparticles using the process described by 
Al Thaher et al. 38  for each of the compounds employed The particles were coated with 5 quadruple 
layers, deposited onto a glass watch and allowed to dry in a fume hood. 
2.6 Silica-antibiotic nanocarriers characterisation 
2.6.1 Transmission electron microscopy (TEM) 
Size and shape of the nanoparticles were determined through transmission electron microscopy 
(TEM); 4 µl droplet of conjugates suspension were deposited on a plain carbon-coated copper TEM 
grid, water was evaporated under ambient laboratory conditions for several hours. Bright field TEM 
images were obtained using a TEM (Philips CM12, FEI Ltd, UK) operating at 80kV fitted with an X-
ray microanalysis detector (EM-400 Detecting Unit, EDAX UK) utilising EDAX’s Genesis software. 
Images (magnification of the images was x 100000) were recorded using a SIS MegaView III digital 
camera (SIS Analytical, Germany) and analysed with ImageJ; the diameter of at least 100 particles 
was determined for each type of nanoparticles. 38  
  
2.6.2 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) was performed using a Stanton Redcroft, STA-780; data were 
recorded from 25 to 600 °C with a constant heating rate of 10 °C min-1. 38  
2.6.3 Zeta potential 
Approximately 2 mg sample were dispersed in 1 ml of acetic buffers (0.1 M) at pH 5. The suspension 
was vortexed and transferred to a capillary cell and the zeta potential was measured immediately 
using Zetasizer ZEN 3600, Nano Series (Malvern, UK). 38    
2.6.4 Gentamicin release  
10 mg of NPs were incubated in 1 ml sterile PBS at 37 °C. Every day all media was replaced with 
fresh sterile PBS. Gentamicin contained in the release media was quantified thorough fluorescence 
spectroscopy using o-phthaldialdehyde (OPA); in a black 96 wells plate, 70 l of media containing 
antibiotic were mixed with 70 l of iso-propanol and 70 l of OPA reagent; after 30 min at room 
temperature in the dark, the fluorescence was determined (excitation wavelength = 340 nm and 
emission wavelength = 450 nm) with a fluoroscan (FLUOROstar Optina, BMG Labtech); standards of 
known gentamicin concentration were also analysed simultaneously to provide calibration. 38  
All characterisations were carried out on nanoparticles obtained from at least three independent 
batches; results are presented as mean ± standard deviation. 
 
2.7 Bone cement preparation 
Bone cement preparation was carried out according to manufacturer and ISO5833:2002 (Implants for 
surgery-Acrylic resin cements) instructions. All the contents of the bone cement were stored at 
recommended conditions and conditioned to room temperature for 2 hours before mixing.  
The solid component (poly-methyl-methacrylate (83.8% w/w); BaSO4 (10.0% w/w); benzoyl 
peroxide (1.9 %w/w) and the liquid component (methyl-methacrylate (97.5 %w/w) and N,N-
dimethyl-p-toluidine (2.5% w/w) were weighed separately. Gentamicin sulphate (4 % w/w) or coated 
silica nanoparticles (15 % w/w) were added to the solid phase. Finally, both components were hand 
  
mixed (solid to liquid ratio 2.1:1) in a polypropylene bowl with a polypropylene spatula for 1 minute, 
before being filled into a cylindrical mold (6 mm diameter and 12mm height). After applying the 
cement, the mold was pressed between two steel endplates covered with PTFE film. After 2 hours, the 
samples were pushed out of the mould using a steel rod and rough edges were sanded down with 
silicon carbide paper (320 grit). Samples were allowed to cure for 24±2 hours at 23ºC prior further 
experiments. 
  
2.8 Bone cement characterisation 
2.8.1 Gentamicin release  
Bone cement cylinders were incubated in 3 ml sterile PBS at 37 °C. Every day all media was replaced 
with fresh sterile PBS. Gentamicin contained in the release media was quantified thorough 
fluorescence spectroscopy using o-phthaldialdehyde (OPA); in a black 96 wells plate, 70 l of media 
containing antibiotic were mixed with 70 l of iso-propanol and 70 l of OPA reagent; after 30 min at 
room temperature in the dark, the fluorescence was determined (excitation wavelength = 340 nm and 
emission wavelength = 450 nm) with a fluoroscan (FLUOROstar Optina, BMG Labtech); standards of 
known gentamicin concentration were also analysed simultaneously to provide calibration. 38  
All characterisations were carried out on nanoparticles obtained from at least three independent 
batches; results are presented as mean ± standard deviation. 
2.8.2 Antimicrobial activity 
Clinical isolates (species determined through PCR) and catalogue strains (S. aureus NCIMB 9518, S. 
aureus ATCC 25923, S. aureus ATCC 9144, S. epidermidis ATCC 12228, MRSA NCTC 12493, S. 
pyogenes ATCC 12344, E. coli NCTC 14418, P. aeruginosa PA01, A. baumannii NCIMB 9214) of 
bacteria commonly associated with prosthetic joint infections were stored on BHI Agar plates at 4 °C. 
A loopful of cells was used to inoculate 10 ml of BHI broth that was then incubated at 37 °C statically 
for 24h. The bacteria suspension was diluted in fresh sterile BHI broth (1:1000) and used to inoculate 
the bone cement release medium after each day of antibiotic release; in a 96 wells plate 20 μl of 
  
diluted cells suspension were diluted with 100 μl of release buffer. Assessment of bacteria growth was 
performed after incubation for 24 hours at 37 degree on three independent cell cultures and triplicate 
release buffers. Results are presented as the day associated to the last release medium capable of 
preventing bacterial growth. 
2.9 Cytocompatibility 
Human osteoblast cells (Saos-2) ATCC HTB-85 were cultured in RPMI-1640 medium as previously 
described.39  
Bone cement samples were sterilised with 70% alcohol and washed three times with sterile PBS prior 
to use. Samples were placed in 24 wells plates containing 2 ml of osteoblast cells suspension prepared 
as described above. Osteoblasts were incubated with the bone cement at 37 °C in humidified atmosphere 
with 5% CO2 for up to 21 days changing medium twice a week. 
2.9.1 MTT 
Osteoblast were incubated on the bone cement samples for 2 days then they were transferred to a clean 
24 well plate with 2 ml of fresh medium without red phenol. Osteoblast cells viability was assessed 
using the MTT assay (Sigma, UK) as described in Perni et al. 39  Results are presented as the average 
and standard deviation of 3 independent bone cement samples. 
2.9.2 Osteoblast mineralisation activity (Alizarin Red A) 
Osteoblast were incubated on the bone cement samples for 21 days, when the medium was removed 
from all wells. After fixing the cells with glutaraldehyde, alizarin red staining (ARS) was carried 
according to the procedure described in Tommasi et al. 39 All mineralisation tests were performed in 
triplicates. 
2.9.3 Microscope imaging 
Saos-2 cells were cultured on the bone cement samples for 4 days; after this time cells were washed 
thoroughly three times in PBS. Cells were then fixed with 3.7% (w/v) formaldehyde in PBS at room 
temperature for 5 min and permeabilised with 0.1%Triton X-100 at room temperature for 5 min. Then 
cells were stained with 50 mg/L of tetramethyl rhodamine B isothiocyanate-conjugated phalloidin 
  
(Sigma-Aldrich, St. Louis, MO, USA) for 40 minutes at room temperature, followed by incubation 
with 5 mg/l of trihydrochloride Hoechst 33342 (Thermo Fisher Scientific, Eugene, OR, USA) for 10 
minutes in the dark. After washing with PBS, samples were mounted and examined using LSM 880 
upright confocal laser scanning microscope with Airyscan (Zeiss, Oberkochen, Germany) for 
visualization of the staining with a 63X magnification objective. Processing of the obtained images 
was conducted using ZEN imaging software (Zeiss). 
2.10 Material properties of bone cement containing nanocarriers 
2.10.1 Bone cement curing time 
Rheological measurements were performed using a strain controlled rheometer, ARES (TA 
Instruments) equipped with 8 mm diameter plates. 
Analysis was carried out in the linear regime by performing dynamic time sweep tests at constant 
frequency (1 rad/sec) and strain (0.1%). Tests were conducted at controlled room temperature. For all 
tests, the bone cement solid phase, with gentamicin (2 % w/w or equivalent amount contained in 
developed Si nanocarriers), was mixed with the liquid phase, quickly with a spatula; the mixture was 
deposited onto the lower plate and experiments were started as fast as possible. To account for the 
time elapsed during mixing and pouring, a timer was started at the moment of mixing the liquid with 
powders. Measurement of complex Young modulus and phase angle were taken every 6 s for up to 15 
min.   
2.10.2 Water uptake  
Bone cement cylinders were weighted before being employed in gentamicin release studies and after 
each day when the release media was replaced. 
2.10.3 Compressive and bending strength 
Compression and bending tests were undertaken on the Zwick Roell ProLine table-top Z050/Z100 
materials testing machine according to BS ISO 5833:2002.  The compression tests were conducted at 
a constant cross-head speed of 20.0 mm/min to produce a curve of displacement against load. For 
each specimen, the compressive strength of the bone cement was determined by dividing the force 
  
applied to cause fracture by the original cross-sectional area of the cylinder. Bending modulus and 
bending strength were estimated according to BS ISO 5833:2002.    
The results are presented in all cases as average of five specimens ± standard deviation.  
2.10.4 Fracture toughness 
Fracture toughness of cement samples was determined according to ISO13586:2000. The bone cement 
samples were rectangular (Length = 45±0.1 mm, Width = 10±0.1 mm and Depth = 3.3±0.1 mm. A sharp 
razor blade was used to create a V-shaped notch of 4.4-5.5 mm at the centre of the sample. The 
rectangular sample was loaded incrementally using a Zwick Roell ProLine table-top Z050/Z100 
materials testing machine (Zwick Testing Machines Ltd., Herefordshire, UK). The fracture toughness 
is a three-point test, where the distance between the rollers is 40mm. The length of the crack was 
measured by a Pye Scientific travelling microscope (Pye Scientific, Cambridge, UK), and the width and 
length of each sample was measured by a Vernier calliper.  
The results of critical stress intensity and critical energy are presented as mean of five samples.  
2.11 Statistical analysis 
The comparison of the effects of Si nanoparticles on Saos-2 cells metabolic activity (viability and 
alizarin Red A assay) were performed using ANOVA test.  
The comparison of nanocarriers on the release profiles was carried out fitting a generalised linear 
mixed model after logarithmic transformation of the gentamicin concentration values using the 
identity link function; followed by ANOVA test and Tukey’s post hoc test of individual pair of data 
sets (p<0.05). Multivariate analysis of variance (MANOVA) was carried out to test the antimicrobial 
activity of nanocarriers against the commercial formulation, where the multiple dependent variables 
were the number of days the growth was prevented, using the Pillai test. Paired-wise ANOVA 
comparison was further performed to determine the impact on individual species. 
All statistical analysis was performed using R (R Core Team, 2012) and lme4 package 40 . 
 
  
3 Results 
3.1 Polymer kinetics of hydrolysis 
No appreciable reduction of polymer MW accountable to hydrolysis in PBS of both PBAE was 
detected for up to 10 days (Figure 1b). 
3.2 Silica nanoparticles properties 
3.2.1 Size 
The silica nanocarriers were spherical and with a diameter of about 50 nm and a Gaussian distribution 
(Figure 2a and d), the deposition of 5 quadruple layers through LbL did not impact the particles 
diameter regardless of the PBAE used (Figure 2 a, b and c).  
3.2.2 Zeta potential 
The amino functionalised nanoparticles had a positive charge (Figure 2e) of +22 mV; during LbL the 
zeta potential of the particles after each layer deposited had a see-saw profile. After the deposition of 
alginate, the particles had negative charge of about -30 mV while after the deposition of gentamicin 
the charge was slightly positive (+4 mV). When any of the PBAEs tested (POLY1 or POLY2) were 
layered on the nanoparticles surface the zeta potential became +8 mV. 
 
  
 
Figure 2. Examples of TEM images (bar equivalent to 500 nm) for uncoated Silica nanoparticles (a) 
or after deposition of 5 quadruple layers using POLY1 (b) and POLY2 (c); size distribution of 
uncoated silica nanocarriers (d). Zeta potential after each deposited layer on silica nanoparticles for 
the first two quadruple layers (e)  for POLY1 and  for POLY2 (f) Examples of thermograms for 
amino functionalized silica nanoparticles (dashed line) and silica nanoparticles layered with 5 
quadruple layers of alginate – gentamicin - POLY1 (solid line) – alginate or alginate – gentamicin – 
POLY2 (dash-dot line) – alginate. 
 
 
  
3.2.3 TGA 
The thermograms of the silica nanoparticles revealed a mass loss with increasing temperature 
reaching a plateau at about 700°C (Figure 2f); furthermore the amount of deposited layers can be 
determined as the difference between the mass loss of the coated and uncoated nanoparticles. TGA 
showed that the organic content (due to LbL deposition) was comparable for the two PBAEs used and 
represented approximately 25% w/w of the prepared nanocarriers. 
3.3 Gentamicin release 
Gentamicin release kinetics from the coated nanoparticles was highest at the beginning and 
monotonically decreased down to 0 after about 25 days for both polyelectrolytes used; nanoparticles 
coated through LbL using POLY1 had an overall higher released and corresponding loading (Figure 
3a); the estimated antibiotic loading on the nanocarriers was ~12 and 10% w/w for POLY1 and 
POLY2 respectively. Gentamicin release from the bone cement was highest at the beginning; the 
greatest amount of gentamicin was released from the PMMA bone cement containing the drug in its 
pure form (Figure 3b) and representing a commercial formulation of antibiotic laden bone cement. 
However, the release of the antibiotic was almost finished after about 5-6 days when gentamicin was 
simply mixed in the PMMA dough. On the other hand, for the antibiotic was deposited on silica 
nanoparticles using the LbL technique and PBAEs, gentamicin was released from the bone cement 
samples for about 25 days (Figure 3b). When POLY2 was employed as polyelectrolyte, gentamicin 
release was greater during the first 2-3 days than POLY1 but the overall amount of drug released at 
the end of the release period (30 days) was greater for POLY1. 
 
Fitting of the release profile with a mixed effect model (Table S1) revealed that when POLY1 or 
POLY2 were employed gentamicin release kinetics followed a first order model (Figure S1) moreover 
visual inspection of residual plots did not reveal any obvious deviations from homoscedasticity or 
normality (Figure S2). On the contrary the commercial formulation release profile was not well fitted 
by this release model as clearly evident in the plots of residuals (Figure S2).  Moreover, the release 
kinetic from Si nanocarriers prepared using POLY1 was lower than for POLY2 (p <0.00034) and both 
  
were lower than the commercial formulation (p <0.0001).  
 
Figure 3. Cumulative release of gentamicin from coated silica nanoparticles (a), PMMA bone cement 
as % of the initial amount of antibiotic (b) when added as pure powder () or deposited on silica 
nanocarriers through LbL using POLY1 () or POLY2 (). Number of days of antimicrobial 
activity of the release media of PMMA bone cement containing gentamicin when added as pure 
powder () or deposited on silica nanocarriers through LbL using POLY1 () or POLY2 () as 
polyelectrolyte for catalogue bacterial strains (c) and clinical isolates of prosthetic joint infections (d). 
 
3.4 Antimicrobial activity 
The antimicrobial activity of the bone cement was tested by inoculating the buffer containing the 
released drug with various bacteria species. The release buffer was changed daily, therefore, each day 
the amount of drug contained was representative of the release kinetic after that certain period of time. 
The antibiotic released from the PMMA bone cement matrix decreased monotonically with increasing 
contact time with the buffer; hence, at some point, it inevitably fell below the minimum inhibitory 
  
concentration for a specific species. The longer the antibiotic was released, the longer the buffer was 
capable of preventing bacterial growth. For example, if no growth was recorded in the buffer collected 
after 14 days of release but growth was noticed in the buffer collected the following day (after 15 
days), it was said that the bone cement was capable of preventing the growth of the specific species 
for 14 days. 
The bacterial tested had species specific sensitivity to gentamicin (Table S2 and S3), and the bone 
cement exhibited antimicrobial activity against all the species tested. The more resistant species from 
the catalogues strains employed was MRSA (only prevented from growing by buffers corresponding 
to a release time < 3days) while the more sensitive was S. epidermidis that was inhibited even by a 
release buffer collected after 24 days (Figure 3c). 
A similar pattern (gentamicin deposited on Si through LbL providing extended antimicrobial activity 
compared to pure form) was observed also for clinical isolates of prosthetic joint infections (PJI), 
even though the isolates were generally more resistant to gentamicin than the catalogue strains (Figure 
3d). Moreover, not antimicrobial activity was observed from bone cement samples containing coated 
nanoparticles using only polyelectrolytes.  
For each species the release buffer from PMMA bone cement containing pure gentamicin gave the 
shortest antimicrobial activity for all bacteria tested (p<0.05) apart S. epidermidis ATCC 12228 as 
revealed by MANOVA and subsequent ANOVA on specific species; on the contrary, the bone cement 
containing the antibiotic deposited through LbL using POLY1 gave the longest antimicrobial effect 
(Figure 3c and d). MANOVA performed on the antimicrobial outcome of POLY1 and POLY2 
nanocarriers added to PMMA bone cement revealed that Si nanocarriers prepared using POLY1 
provided an antimicrobial activity significantly different (p < 0.05) from Si nanocarriers prepared 
using POLY2 only for the following species: S. pyogenes ATCC 12344; A. baumannii NCIMB 9214, 
E. coli NCTC 10418; P. aeruginosa PA01; K. pneumoniae 59294; S. pneumoniae 59413; E. coli 
59284; P. acnes 53749. 
  
3.5 Bone cement properties 
3.5.1 Water uptake 
Water uptake by the bone cement sample was determined up to 1 month of contact with fluid. The 
greatest uptake was recorded during the first day of immersion in the buffer and gradually the amount 
of fluid contained in the samples stabilised, reaching a plateau after about 7 days (~13 h0.5); no 
difference was found between the PMMA bone cement samples containing pure gentamicin or the 
silica nanocarriers (Figure 4). 
 
Figure 4. Water uptake of PMMA bone cement with added gentamicin as pure powder () or 
deposited on silica nanocarriers through LbL using POLY1 () or POLY2 () as polyelectrolyte. 
 
  
3.5.2 Bone cement settling time 
Bone cement polymerisation was analysed through rheology, determining the variation of the material 
properties with time. For all types of bone cement tested (commercial formulation with gentamicin or 
added Si NP), initial values of the storage modulus (G’) and loss modulus (G’’) were comparable and 
the ratio tan delta (G”/G’) was about 1. During sample curing G’ showed a monotonical “S-shaped” 
increase after mixing, reaching a final plateau value of about 108 Pa. The loss modulus (G”) exhibited 
an initial slow increase, followed by a quick local maximum corresponding to the faster growth in G’, 
finally decreasing to a plateau value (about 106 Pa) (Figure 5). The corresponding tan delta (G”/G’) 
profile exhibited a general decline with a local maximum corresponding to the inflection in G’. The 
time required by the bone cement to cure was chosen as the point of local maximum in tan delta. 
Commercial formulation required 8.92 min (Figure 5d) and the addition of any of the Si NP based 
gentamicin delivery system impact on the curing time of the bone cement was not statistically 
significant (p > 0.05).   
 
Figure 5. Time dependent rheological measurements during curing for bone cement with added 
gentamicin as pure powder (a) or deposited on silica nanocarriers through LbL, by using POLY1 (b) 
  
or POLY2 (c) as polyelectrolyte, G’ (), G” () and tan delta (). (d) Curing times in minutes 
(mean and standard deviation) of PMMA bone cement with and without added nanoparticles. 
 
  
Figure 6. (a) Compressive strength (); (b) bending modulus () and bending strength ()  and (c) 
Critical stress intensity () and critical energy () of PMMA bone cement with added gentamicin as 
pure powder or deposited on silica nanocarriers through LbL using POLY1 or POLY2. 
 
3.5.3 Mechanical properties 
Comparison of compressive and bending properties of the PMMA bone cement with added 
nanocarriers against bone cement with the same amount of gentamicin in powder form did not reveal 
any adverse effect of the silica nanoparticles (Figure 6), similarly resistance against fracture 
propagation was not affected; moreover, these values were matching the requirement for applicability 
as PMMA bone cement 32 . 
3.5.4 Osteoblast cytocompatibility 
Human osteoblast grown on the commercial formulation or on bone cements containing the silica 
nanocarriers had the same viability (assessed through MTT) and calcium production (Alizarine Red) 
as shown in (Figure 7). Moreover, the conformation of the actin filaments of Saos-2 cells grown on 
bone cement containing the developed nanocarriers did not differ from that of cells seeded on the 
commercial formulation containing gentamicin powder (Figure 8).    
  
 
Figure 7. MTT (a) and Alizarin Red A (b) assay of Saos-2 (human osteoblast) cells grown on PMMA 
bone cement containing gentamicin as pure powder () or deposited on silica nanocarriers through 
LbL using POLY1 () or POLY2 () as polyelectrolyte. 
 
  
 
Figure 8. Microscope images of Saos-2 cells, grown on PMMA bone cement containing gentamicin as 
pure powder (a) or deposited on silica nanocarriers through LbL using POLY1 (b) or POLY2 (c) as 
polyelectrolyte, stained with phalladolin (actin) in red and DAPI in blue exposed. bar represent 10 
m. 
  
4 Discussion 
In our work we took an holistic approach to the development of a drug delivery system for PMMA 
bone cement using gentamicin as a model drug in virtue of its wide use for this purpose; first we 
characterised the nanocarriers, then we assessed the release profile to ascertain that the drug release 
profile was sustained for up to a month when the nanocarriers were embedded in the actual PMMA 
and that the antimicrobial activity of the antibiotic was retained and finally we verified that no other 
properties of the PMMA bone cement were negatively impacted by the inclusion of the drug delivery 
system into the PMMA bone cement matrix. 
4.1 Silica nanoparticles properties 
The silica nanocarriers characterisation was carried out through TGA that is routinely employed to 
determine the fraction of organic material in a sample as the mass loss during heating is associated to 
the combustion of the organic molecules present. The mass loss observed in the Si-NH2 was due to 
functionalisation with APTS that introduced some organic content on the nanoparticles surface. Also 
the LbL coating with the two different polymers resulted in similar amount of drug/polyelectrolytes 
deposited (Figure 2) and about 3-4% each quadruple layer, moreover the thickness of the coating was 
negligible as seen in the TEM images (Figure 2); both results are in agreement with the general trend 
observed in other works 34 ,38 . 
The zeta potential of the functionalised particles pre LbL (+20 mV) was due to the presence of the 
amino groups present in the APTS and similar to those reported previously 16 ,38 . The zig-zag pattern 
observed during the LbL is typical of the process 41 ,42  and the lowest value (-30 mV) corresponds to 
the pure alginate in the same buffer (pH =5) while the values of +8 mV and +4 mV are those 
corresponding to the pure PBAE and gentamicin. The observation that after each deposited layer the 
zeta potential of the particle surface was equivalent to that of the pure coating molecule 
(polyelectrolyte or drug) indicated that the surface was fully covered and that the process parameters 
(concentration, pH and time) were correct. 
  
4.2 Gentamicin release 
The highest concentration of gentamicin, observed after the first 24 hours in contact with the release 
buffers, was about 0.3 mg/ml for all samples; as the solubility of gentamicin is at least 10 mg/ml (as 
used in the LbL protocol), sink conditions were achieved (ratio between fluid concentration and 
maximum solubility was at ~30 and the minimum required is 3).43   
The release from the LbL coated nanocarriers is a process governed by two distinct mechanisms, 
diffusion of the drug through the deposited layers and the delamination of the coating due to 
polyelectrolyte hydrolysis 38 ,44 . The hypothesis that led to the numerous applications of PBAEs in 
LbL for biomedical application is their ability to undergo hydrolysis and thus release the drug 
entrapped in the LbL coating 44 -47 . Such view was recently confuted with evidences suggesting that 
drug diffusion through the deposited layers is in fact the controlling mechanism 38 . In this work, we 
used two different polymers compared to Al Thaher et al.38 , even though still PBAEs, consequently, 
the positive fitting of the release profile with a first order kinetic model further reinstates that the 
controlling mechanism when PBAEs are employed in LbL is diffusion and not hydrolysis of the 
polyelectrolyte that would have determined a zero order kinetic of release (constant release 
throughout until all drug is released); furthermore no hydrolysis was detected for either PBAEs for at 
least 10 days (Figure 1). Antibiotic loading on the carriers was estimated as described by Al Thaher et 
al.38 and comparable to the results presented for nanoparticles coated with 5 quadruple layers. 
In this work PMMA bone cement containing gentamicin powder (4% w/w) was used as control as this 
represents a commercial formulation of antibiotic laden bone cements. Despite the lower amount of 
gentamicin present in the bone cement samples when loaded onto the nanocarriers, as the loading of 
the gentamicin onto the nanoparticles was about ~12% and the nanoparticles were added to 
concentration of 15% w/w, the release profile of the antibiotic from PMMA bone cements containing 
the developed delivery systems was considerably longer (Figure 3b). It was also observed that the 
release from the commercial formulation did not follow a first order kinetic; hence confirming the 
questionable suitability of simply mixing antibiotics in PMMA bone cement if prolonged and 
controlled release is sought. Moreover, from a mass transfer phenomenon stand point, the release of 
  
gentamicin from the commercial bone cement depends only on the diffusion of the antibiotic in the 
PMMA matrix; on the other hand when the Si nanocarriers are added, as they distributed 
homogeneously in the PMMA bone cement matrix as seen in Figure S3, the overall gentamicin 
release is the sum of the diffusion first through the LbL coating and then through the PMMA matrix. 
The overall kinetic of diffusion through multiple phases is controlled by the slowest of the diffusion 
kinetics. Therefore, if diffusion through the LbL coating was “faster” than diffusion through PMMA 
bone cement, the addition of Si nanocarriers would result in the same release profile between 
commercial formulation and bone cement with the drug delivery system as, regardless of the ability of 
the antibiotic to migrate through the LbL coating, the overall diffusion would be controlled by the 
diffusion through the PMMA phase. On the contrary, if the diffusion through the LbL coating was 
“slower”, the release profile between commercial formulation would exhibit a quick release kinetic 
than the samples containing the Si nanocarriers; moreover bone cement containing the nanocarriers 
would also would show a release profile similar to that of the Si nanocarriers simply suspended in 
solution as only the antibiotic that is continuously released from the nanocarriers can be transported 
through the PMMA bone cement matrix. Our results (Figure 3a and b) demonstrate that the release 
from the nanocarriers is the controlling step in the overall antibiotic release process from bone 
cement. The prolonged released from the bone cement resulting from the use of the coated silica 
nanocarriers is due to gentamicin becoming available after diffusing through the LbL coating as time 
progresses while in commercial formulation all the antibiotic is available from the beginning. 
Of the total antibiotic initially contained in the PMMA bone cement samples, more was released when 
silica nanocarriers were used (>-50%) while when gentamicin powder was simply mixed only 15% 
was released (Figure 3b). The later observation is consistent with literature 48 ,49  and the general 
explanation is entrapment inside the PMMA matrix preventing the antibiotic migration from the 
PMMA bone cement bulk to the surface. However, the greater amount of antibiotic capable of leaving 
the PMMA bone cement when the silica nanocarriers were used could also be the result of the 
protection of the drug from the potentially damaging radical species that drive the polymerisation 
reaction during bone cement curing. This protective action would not be available to the drug 
molecules when simply mixed as in the commercial formulation. Hence, the known fact that only 
  
about a fifth of antibiotic contained in the PMMA bone cement is released would not be due to 
entrapment but to drug damage during bone cement curing. It is well known that gentamicin, like 
tobramycin, can survive high temperatures (even autoclave) and this is one of the reasons for their use 
in bone cements where the radical polymerisation reaction can result in temperatures as high as 60-70 
°C,; however the ability to withstand high temperature does not necessarily mean resistance to 
radicals. This protective hypothesis would also explain the similar result observed when gentamicin 
was introduced in PMMA bone cement through liposome 37 . 
4.3 Antimicrobial activity 
Despite the remarkable prolonged release of gentamicin when the nanocarriers were employed 
compared to the commercial formulation where the drug is mixed, it was critical to assess the ability 
to prevent bacterial growth as the released drug could not provide the required effect in virtue of the 
nanocarriers preparation and subsequent release; similarly bone cement nanocarriers prepared using 
only alginate and POLY1 or POLY2 were tested to identify any possible antimicrobial activity due to 
the polyelectrolytes. 
The antimicrobial test was especially designed to evaluate the length of the antimicrobial period 
exhibited by the PMMA bone cement containing the drug delivery system and the bacterial species 
tested represent the typical pathogens found in PJI 50 -52 .  
The principle is based on the fact that bacteria are able to grow in any media when the concentration 
of antibiotic is below a certain value (MIC) that depends on the specific bacteria strain. The 
concentration of gentamicin in the release buffer decrease with time; hence the microorganisms will 
only be able to growth in release media collected after a certain time (as the release buffer was 
changed daily). The absence of antimicrobial activity from the control sample was a confirmation of 
the cytocompatibility of the polyelectrolytes employed in the LbL assembly process. The 
susceptibility to the antibiotic released varied among the bacterial species with clinical isolates 
generally more resistant, and it was generally in line with the MIC of gentamicin for the different 
species (supplementary info); furthermore, this observation reinforces the notion that technology are 
better tested using clinical isolates than catalogue strains. PMMA bone cement with mixed gentamicin 
  
powder antimicrobial was capable of preventing growth of many of the bacteria species for about 1 
week, in line with the general expectation; while very weak (low MIC) were inhibited for longer. For 
example, the longest activity was observed against the weakest bacteria (S. epidermidis ATCC12228) 
and terminated when the release terminated. The use of the silica nanocarriers resulted in all the 
bacteria species growth being inhibited by the released antibiotic for longer than in case gentamicin 
powder in agreement to higher the concentrations of antibiotic in the release buffer for longer periods 
of time (Figure 3). Additionally, the PMMA bone cement containing the silica nanocarriers prepared 
using POLY2 for shorter period of time than those prepared with POLY1 was consistent with the 
concentration in the release buffer in contact with POLY2 samples exhibiting lower antibiotic 
concentrations than those with POLY1. 
4.4 Bone cement properties 
The material properties of PMMA bone cement are satisfactory therefore the addition of the silica 
nanocarriers did not have the objective to improve any specific parameter; however, it was important 
to verify that the encapsulation of the developed silica nanocarriers did not have negative impact on 
the PMMA bone cement properties. The mechanical properties (water uptake, compression, bending 
and fracture resistance) did not improve despite the use of nanoparticles that resulted in a 
nanocomposite material; this is likely because the PMMA bone cement contains already a 
considerable amount of inorganic particulate (BaSO4) thus the addition of nanoparticles had a 
negligible impact. Water uptake is due to swelling; when the nanocarriers are used the concentration 
of the polymeric matrix and BaSO4 decreased but the nanocarriers are also capable of water uptake 
compensating for the reduction of these components. 
Rheological properties are important for surgeons as they need enough time to apply the bone cement 
but curing needs to be quick enough to allow speedy patient mobilisation and rehabilitation; current 
surgical techniques require the bone cement to be mixed for about 1-1.5 min and applied in less than 
~5 min from initial mixing. The fact that silica nanocarrier do not alter the curing properties of 
PMMA bone cement would allow orthopaedic surgeons to perform joint replacement operation 
  
without having to change their technique so retraining would not be required hence reducing time and 
cost associated to switching to the novel bone cement.   
Another important assessment of the novel PMMA bone cement was the response of osteoblast cells 
when in contact with such material compared to the commercial formulation. No only cell viability 
but also other aspect of osteoblast metabolism such wall morphology and calcium production was 
assessed and no detrimental impact of the nanocarriers observed in any of these. Particularly calcium 
production is linked to the ability of the cells to integrate the abiotic surface into the bone while the 
alteration of the cell morphology could indicate inflation with the possible alteration of the balance 
between osteoblasts and osteoclasts toward the former cell type with consequent bone resorption 
overtaking bone formation; a process well known to result in aseptic loosening and joint replacement 
failure. 
4.5 Conclusions 
PMMA bone cement containing antibiotic is the gold standard material used during joint replacement 
device implantation to fix the device in place and to provide a source of antimicrobial agent to prevent 
infection offset after surgery. Despite the wide diffusion of this material, infections still pose a major 
threat to patient undergoing this type of orthopaedic procedures; predominantly because the antibiotic 
is fast released from the bone cement while infection can establish well after surgery even months. 
To overcome this limitation, we have developed novel antibiotic nanocarriers depositing the drug on 
the surface of silica nanoparticles using the Layer-by-Layer technique and hydrolysable and 
inexpensive polyelectrolytes (poly beta amino esters). 
When the antibiotic was added to PMMA bone cement using these new drug delivery systems, drug 
release and the antimicrobial activity were protracted to almost 1 month compared to ~ 1 week the 
commercial formulation. The prolong antimicrobial activity was not achieved compromising any of 
the multitudes of bone cement properties tested hence the newly developed nanocarriers can provide a 
viable solution to the fight against late prosthetic joint infection that pose a serious rick to patient 
quality of life with potentially lethal consequences and constitute a significant economic burden to the 
financial resources of the health care providers.  
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